New PCSK9 Inhibitor Recaticimab Slashes Bad Cholesterol by 53mg/dL in Clinical Trials

High cholesterol accelerates cardiovascular aging and remains a leading cause of heart disease worldwide. Despite statin therapy, many patients struggle to reach optimal cholesterol targets, creating an urgent need for more effective treatments that support healthy aging.

Researchers conducted a systematic review and meta-analysis of four randomized controlled trials testing recaticimab, a novel injectable medication that blocks PCSK9, a protein that prevents cholesterol removal from blood. The analysis included 1,657 patients with dyslipidemia who received either recaticimab or placebo injections.

The results were striking. Recaticimab reduced LDL (bad) cholesterol by an average of 53 mg/dL, non-HDL cholesterol by 47 mg/dL, and apolipoprotein B by 44 mg/dL compared to placebo. It also decreased triglycerides by 9 mg/dL and lipoprotein(a) by 29 mg/dL. These reductions represent substantial improvements in cardiovascular risk markers that typically predict longer, healthier lifespans.

Safety analysis showed recaticimab was generally well-tolerated, with no significant increases in serious adverse events, liver enzyme elevations, or respiratory infections compared to placebo. The main side effect was injection site reactions, occurring more frequently than with placebo but remaining manageable.

For health-conscious individuals focused on longevity, this represents a potentially powerful tool for optimizing cardiovascular health, especially when combined with lifestyle interventions. However, the studies were relatively short-term and conducted in limited populations, so long-term safety and efficacy in diverse groups requires further investigation.